Bluebird bio Inc

NASDAQ:BLUE  
30.32
+1.01 (+3.45%)
Products

U.S. FDA Accepts For Priority Review Bristol Myers Squibb And Bluebird Bio Application For Anti-BCMA Car T Cell Therapy Idecabtagene Vicleucel

Published: 09/22/2020 11:36 GMT
Bluebird bio Inc (BLUE) - U.S. Food and Drug Administration (fda) Accepts for Priority Review Bristol Myers Squibb and Bluebird Bio Application for Anti-bcma Car T Cell Therapy Idecabtagene Vicleucel (ide-cel, Bb2121).
Bristol-myers Squibb Co - FDA Set a Target Action Date of March 27, 2021.
Bristol-myers Squibb Co - Bla is Based on Results From Pivotal Phase 2 Karmma Study.